Quick Answer
Ensysce Biosciences, Inc. reported R&D Expense of $10.38 million for fiscal year 2025.
Ensysce Biosciences, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $10.38M | +43.7% |
| 2024 | $7.22M | -4.9% |
| 2023 | $7.59M | -61.7% |
| 2022 | $19.84M | +322.9% |
| 2021 | $4.69M | +6.8% |
| 2020 | $4.39M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.95M | +74.8% | +53.6% |
| June 30, 2025 | $1.92M | +103.1% | +2.0% |
| March 31, 2025 | $1.89M | +142.1% | +11.5% |
| September 30, 2024 | $1.69M | -11.7% | +78.5% |
| June 30, 2024 | $947.2K | -42.4% | +21.6% |
| March 31, 2024 | $778.9K | -56.6% | -59.3% |
| September 30, 2023 | $1.91M | -59.7% | +16.5% |
| June 30, 2023 | $1.64M | -69.1% | -8.5% |
- Ensysce Biosciences, Inc. showed an increase of +43.7% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Ensysce Biosciences, Inc.’s r&d expense has grown by 136.4% (from $4.39 million to $10.38 million).
- The most recent figure is from Ensysce Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: